Flu Hospitalizations in Nursing Homes Reduced by Quick, Widespread Preventive Antiviral Treatment

Why It Matters

Accelerated, broad antiviral use cuts costly hospital admissions, easing strain on Medicare and improving resident safety during flu outbreaks.

Key Takeaways

• Intensive prophylaxis treats ≥70% residents within two days.
• Hospitalizations drop 14 days after rapid antiviral rollout.
• Mortality rates unchanged despite reduced hospital admissions.
• Broad treatment includes unaffected units to curb spread.
• Guidelines may shift toward mandatory two‑day prophylaxis.

Pulse Analysis

Influenza remains a leading cause of acute illness and hospital transfers among long‑term care residents, straining both clinical staff and Medicare budgets. Traditional outbreak responses often rely on symptom‑based testing and targeted treatment, which can lag behind viral spread in densely populated facilities. The recent JAMA Internal Medicine study highlights that administering oseltamivir prophylactically to the majority of residents within 48 hours dramatically curtails severe cases. By shifting the focus from reactive care to pre‑emptive chemoprophylaxis, operators can protect vulnerable populations while easing pressure on emergency services.

The retrospective cohort examined 404 flu outbreaks across 318 U.S. nursing homes, covering more than 35,000 resident‑days between 2018 and 2022. Facilities that achieved intensive prophylaxis—defined as treating at least 70 % of eligible residents within two days—experienced a statistically significant reduction in 14‑day hospitalizations, with a similar but less precise trend at 30 days. Mortality, however, did not differ, suggesting that while antivirals blunt severe disease requiring admission, they do not alter the underlying risk of death once infection occurs. These results underscore speed and coverage as the critical variables.

Given the clear hospitalization benefit, policymakers and senior‑care administrators are likely to revise infection‑control protocols to mandate rapid, facility‑wide antiviral distribution once an outbreak is confirmed. The cost of a short course of oseltamivir—approximately $15‑$20 per resident—pales in comparison to the average $15,000 Medicare expense of a flu‑related hospital stay, making the intervention economically attractive. Moreover, the study’s suggestion to treat even non‑affected units could serve as a template for managing other respiratory threats, such as RSV or COVID‑19 variants, where early chemoprophylaxis may similarly limit severe outcomes.